López MM, Olvera CS

Language: Spanish
References: 9
Page: 117-121
PDF size: 59.08 Kb.

ABSTRACT

New indications for permanent cardiac pacing have been developed in recent years, with numerous studies demonstrating improved clinical outcomes in many disorders. These techniques have been used in hypertrophic obstructive cardiomyopathy and dilated cardiomyopathy, and many physiological bases and clinical studies justify their application. In dilated cardiomyopathy and heart failure with intraventricular conduction delay, abnormal electrical depolarization of the heart results in mechanical asynchrony of the ventricles. Tricameral pacing (atrial-based biventricular) offers an alternative and conditions ventricular synchronization. The MUSTIC study, a controlled, randomized, crossover study, showed promising results, significantly improving exercise tolerance and quality of life, and increasing in diastolic ventricular filling period. Several ongoing randomized, controlled clinical trials should provide more definitive data on safety, efficacy, and decreased mortality. Hypertrophic obstructive cardiomyopathy has many therapeutic approaches such as, medical treatment, dual chamber pacing, surgery, and transcatheter septal ablation. Dual chamber pacing has been shown to improve symptoms and hemodynamic variables in patients severely symptomatic. However, randomized clinical trials (PIC and M-PATHY) have not shown conclusive evidence regarding the long-term benefit from pacing in these patients. Moreover, relationship between reduction in the intraventricular gradient and improvement of symptoms is controversial; there might be a significant placebo effect. Cardiac pacing is an alternative therapy for selected patients with hypertrophic cardiomyopathy, but very careful secreening of patients is mandatory.

REFERENCES

1. Peters RW, Gold MR: Pacing for patients with congestive heart failure and dilated cardiomyopathy. Cardiol Clin 2000; 18: 55-66.

2. Hochleitner M, Hortnagl H, Choi-Keung NG, Hortnagl H, Gschnitzer F, Zechmann W: Usefulness of physiologic dual-chamber pacing in drug-resistant idiopathic cardiomyopathy. Am J Cardiol 1990; 66: 198-202.

3. Gold MR, Fisher ML, Gottlieb SS: Failure of short atrioventricular delay pacing to improve hemodynamic function in patients with congestive heart failure. Heart Web 1996; 2: 100-103.

4. Cazeau S, Leclerco Ch, Lavergne T, Walker S, Varma Ch, Linde C, et al: Effects of Multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873-80.

5. Bryce M, Spielman S, Greenspan A, Kotler M: Evolving indications for pemanent pacemakers. Ann Int Med 2001; 134: 1130-1141.

6. Sorajja P, Elliott PM, McKenna WJ: Pacing in hypertrophic cardiomyopathy. Cardiol Clin 2000; 18: 67-79.

7. Kappenberger L, Linde C, Daubert C, Brecker SJD: Pacing in hypertrophic obstructive cardiomyopathy: A randomized crossover study. Eur Heart J 1997; 18: 1249-1256.

8. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieral RS: Assessment of permanent dual-chamber pacing as a treatment for drug refractory symptomatyc patients with obstructive hypertrophic cardiomyopathy: A randomized, double-blind, cross-over study (M-PATHY). Circulation 1999; 99: 2927-2933.

9. O’Rourke R: Cardiac pacing: An Alternative Treatment for selected patients with hypertrophic cardiomyopathy and adjunctive therapy for certain patients with dilated cardiomyopathy. Circulation 1999; 100: 786-788.